"AstraZeneca’s AL amyloidosis drug fails to impress in Phase III" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

AstraZeneca said its amyloidosis treatment anselamimab failed to reach its primary goal in a final-stage trial.

AstraZeneca PLC (NASDAQ:AZN) is one of Goldman Sachs’ top healthcare stock picks. On July 4, the company secured regulatory ...

AstraZeneca has been developing in China for 30 years, constantly increasing investment and building an efficient supply network, Lin said, noting that last year, AstraZeneca added a new production ...

"Baxdrostat BaxHTN Phase III trials on patients with uncontrolled or treatment-resistant hypertension demonstrated a statistically significant and clinically meaningful reduction in mean-seated ...

"attachment_1220866" align="aligncenter" width="1456"] A laboratory employee in a sterile environment inspecting a microscope ...

AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of ...

AstraZeneca, a United Kingdom-based biopharmaceutical giant, will add 10 to 15 new projects to the company's research and development pipeline in China each year, reflecting its increased investment ...

(Alliance News) - AstraZeneca PLC on Friday said Imfinzi is "poised to transform the standard of care" as it reported the bladder cancer treatment cleared a European regulatory milestone.

Constellation Brands (STZ) Shares in Corona beer-maker Constellation Brands dipped 1.5% in pre-market trading on Wednesday morning, after the company missed quarterly earnings estimates.